• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病性心肌病:病理生理学、影像学评估及治疗策略

Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies.

作者信息

Rizza Vincenzo, Tondi Lara, Patti Angelo Maria, Cecchi Damiano, Lombardi Massimo, Perone Francesco, Ambrosetti Marco, Rizzo Manfredi, Cianflone Domenico, Maranta Francesco

机构信息

IRCCS Ospedale San Raffaele, Milan, Italy.

Multimodality Cardiac Imaging Section, Policlinico San Donato, San Donato Milanese, Italy.

出版信息

Int J Cardiol Cardiovasc Risk Prev. 2024 Sep 28;23:200338. doi: 10.1016/j.ijcrp.2024.200338. eCollection 2024 Dec.

DOI:10.1016/j.ijcrp.2024.200338
PMID:39734497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11681223/
Abstract

Diabetes mellitus (DM) is one of the most prevalent cardiovascular risk factors in the general population, being associated with high morbidity and socioeconomic burden. Diabetic cardiomyopathy (DCM) is a non-negligible complication of DM, whose pathophysiological fundaments are the altered cardiac metabolism, the hyperglycemia-triggered formation of advanced glycation end-products (AGEs) and the inflammatory milieu which are typical in diabetic patients. These metabolic abnormalities lead to cardiomyocytes apoptosis, interstitial fibrosis and mechanical cardiac dysfunction, which can be identified with non-invasive imaging techniques, like echocardiography and cardiac magnetic resonance. This review aims to: 1) describe the major imaging features of DCM; 2) highlight how early identification of DCM-related anatomical and functional remodeling might allow patients' therapy optimization and prognosis improvement.

摘要

糖尿病(DM)是普通人群中最常见的心血管危险因素之一,与高发病率和社会经济负担相关。糖尿病性心肌病(DCM)是DM不可忽视的并发症,其病理生理学基础是心脏代谢改变、高血糖引发的晚期糖基化终产物(AGEs)形成以及糖尿病患者典型的炎症环境。这些代谢异常导致心肌细胞凋亡、间质纤维化和心脏机械功能障碍,可通过超声心动图和心脏磁共振等非侵入性成像技术进行识别。本综述旨在:1)描述DCM的主要影像学特征;2)强调早期识别DCM相关的解剖和功能重塑如何能够优化患者治疗并改善预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/3c0a0eb80df6/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/bd4ebe9ffa87/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/d3036b0845ff/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/b00e254a8340/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/3c0a0eb80df6/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/bd4ebe9ffa87/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/d3036b0845ff/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/b00e254a8340/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ca/11681223/3c0a0eb80df6/gr4.jpg

相似文献

1
Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies.糖尿病性心肌病:病理生理学、影像学评估及治疗策略
Int J Cardiol Cardiovasc Risk Prev. 2024 Sep 28;23:200338. doi: 10.1016/j.ijcrp.2024.200338. eCollection 2024 Dec.
2
Endothelial Dysfunction and Diabetic Cardiomyopathy.内皮功能障碍与糖尿病心肌病。
Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.
3
The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools.心脏纤维化在糖尿病心肌病中的作用:从病理生理学到临床诊断工具。
Int J Mol Sci. 2023 May 11;24(10):8604. doi: 10.3390/ijms24108604.
4
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.糖尿病性心肌病中心脏功能障碍的机制:分子异常与表型变异
Heart Fail Rev. 2023 May;28(3):597-606. doi: 10.1007/s10741-021-10200-y. Epub 2022 Jan 10.
5
Diabetic cardiomyopathy--fact or fiction?糖尿病性心肌病——确有其事还是子虚乌有?
Herz. 2011 Mar;36(2):102-15. doi: 10.1007/s00059-011-3429-4.
6
Western diet given to healthy rats mimics the human phenotype of diabetic cardiomyopathy.西方饮食给予健康大鼠可模拟人类 2 型糖尿病心肌病表型。
J Nutr Biochem. 2018 Nov;61:140-146. doi: 10.1016/j.jnutbio.2018.08.002. Epub 2018 Aug 21.
7
Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats.姜黄素可缓解实验性糖尿病大鼠的糖尿病心肌病。
PLoS One. 2012;7(12):e52013. doi: 10.1371/journal.pone.0052013. Epub 2012 Dec 14.
8
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.糖尿病心肌病中的分子功能障碍和表型紊乱。
Int J Mol Sci. 2019 Jul 2;20(13):3264. doi: 10.3390/ijms20133264.
9
Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape.AMP 激活的蛋白激酶在糖尿病心肌病发展中心血管代谢异常中的作用:分子全景。
Eur J Pharmacol. 2020 Dec 5;888:173376. doi: 10.1016/j.ejphar.2020.173376. Epub 2020 Aug 15.
10
Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell.糖尿病心肌病:从机制到管理简述。
Endocr Metab Immune Disord Drug Targets. 2021;21(2):268-281. doi: 10.2174/1871530320666200731174724.

引用本文的文献

1
miR-451 Is a Driver of Lipotoxic Injury in Patients with Diabetic Cardiomyopathy.miR-451是糖尿病性心肌病患者脂毒性损伤的驱动因素。
Cells. 2025 Sep 8;14(17):1401. doi: 10.3390/cells14171401.
2
Secondary Prevention After Acute Coronary Syndromes in Women: Tailored Management and Cardiac Rehabilitation.女性急性冠状动脉综合征后的二级预防:个性化管理与心脏康复
J Clin Med. 2025 May 12;14(10):3357. doi: 10.3390/jcm14103357.
3
Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.

本文引用的文献

1
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.特征化糖尿病性心肌病:ARISE-HF 试验的基线结果。
Cardiovasc Diabetol. 2024 Feb 1;23(1):49. doi: 10.1186/s12933-024-02135-z.
2
Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy.达格列净对多柔比星+环磷酰胺化疗模式诱导的心肌病的心脏保护作用的可能性。
Int J Cardiol. 2023 Nov 15;391:131331. doi: 10.1016/j.ijcard.2023.131331. Epub 2023 Sep 4.
3
Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts.
口服司美格鲁肽治疗的 A 期和 B 期心力衰竭 2 型糖尿病患者的亚临床变化。
Medicina (Kaunas). 2025 Mar 22;61(4):567. doi: 10.3390/medicina61040567.
4
Incidence and Risk Factors for Developing Type 2 Diabetes Mellitus After Acute Myocardial Infarction-A Long-Term Follow-Up.急性心肌梗死后发生2型糖尿病的发病率及危险因素——一项长期随访研究
J Cardiovasc Dev Dis. 2025 Feb 28;12(3):89. doi: 10.3390/jcdd12030089.
糖尿病性心肌病:国际多学科专家委员会2023年更新版
Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102052. doi: 10.1016/j.cpcardiol.2023.102052. Epub 2023 Aug 26.
4
Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs.糖尿病心肌病:miRNAs 和长链非编码 RNA 的作用。
Front Endocrinol (Lausanne). 2023 Mar 7;14:1124613. doi: 10.3389/fendo.2023.1124613. eCollection 2023.
5
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
6
Diabetes and Myocardial Fibrosis: A Systematic Review and Meta-Analysis.糖尿病与心肌纤维化:系统评价和荟萃分析。
JACC Cardiovasc Imaging. 2022 May;15(5):796-808. doi: 10.1016/j.jcmg.2021.12.008. Epub 2022 Feb 16.
7
Association of myocardial fibrosis detected by late gadolinium-enhanced MRI with clinical outcomes in patients with diabetes: a systematic review and meta-analysis.利用钆延迟增强 MRI 检测的心肌纤维化与糖尿病患者临床结局的相关性:系统评价和荟萃分析。
BMJ Open. 2022 Jan 11;12(1):e055374. doi: 10.1136/bmjopen-2021-055374.
8
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
9
Exercise capacity is related to attenuated responses in oxygen extraction and left ventricular longitudinal strain in asymptomatic type 2 diabetes patients.运动能力与无症状 2 型糖尿病患者氧摄取和左心室纵向应变反应减弱有关。
Eur J Prev Cardiol. 2022 Jan 11;28(16):1756-1766. doi: 10.1093/eurjpc/zwaa007.
10
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用:EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.